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Prediction of Ewing Sarcoma 
treatment outcome using 
attenuated tissue reflection FTIR 
tissue spectroscopy
Radosław Chaber1, Kornelia Łach1, Christopher J. Arthur2, Anna Raciborska3, 
Elżbieta Michalak4, Krzysztof Ciebiera5, Katarzyna Bilska3, Katarzyna Drabko6 & 
Józef Cebulski7
Ewing sarcoma is the second most common type of primary bone cancer and predominantly affects 
children and young people. Improved outcome prediction is key to delivering risk-adjusted, appropriate 
and effective care to cancer patients. Advances in the Fourier Transform Infrared (FTIR) spectroscopy 
of tissues enable it to be a non-invasive method to obtain information about the biochemical content 
of any biological sample. In this retrospective study, attenuated tissue reflection FTIR spectroscopy 
of biopsy samples from paediatric patients reveals spectral features that are diagnostic for Ewing 
Sarcoma. Furthermore, our results suggest that spectral features such as these may be of value for the 
prediction of treatment outcome independent to well-known, routinely used risk factors.
Ewing sarcoma (ES) is a devastating, poorly differentiated, mesenchymal tumour of bones or soft tissues. It is the 
second most common type of primary bone cancer in the US and Europe where it accounts for approximately 
25% to 34% of malignant bone tumours1. ES is rare, affecting about 2.9 people per million annually, however, 
predominantly affects children and young adults under 20 years of age2. This disease accounts for 2% of childhood 
cancers3.
With advances in multimodal therapy, survival rates for patients with localized disease approach 75%4,5. In 
contrast, patients with metastatic, refractory, or relapsed disease have very poor outcomes generally6–8. The 5-year 
survival rate for patients with metastases detected at diagnosis remains around 25% and even around 10% when 
relapse occurs within the first 2 years following treatment9. International studies conducted over the last three 
decades have identified clinically relevant prognostic factors, and clinical characteristics such as age, tumour size 
and site, metastatic pattern and histologic response to the neoadjuvant chemotherapy measured by the percentage 
of viable tumour cells remaining after its completion. Consequently, 18F-FDG PET/CT results are now being 
investigated for future risk-adapted therapies by various groups4,5,10. There remains an unmet need for improved 
prognostic methods which can enable more accurate and effective application of such risk-adapted therapies.
Fourier Transform Infrared (FTIR) Spectroscopy is a non-invasive physicochemical method which measures 
the absorption of infrared radiation from chemical bonds in functional groups of molecules. It is one of the most 
relevant tools to characterize ex vivo tissues because this technique provides bulk information about the bio-
chemical content of a biological sample in contrast with immunohistochemistry or other molecular techniques 
that target one macromolecule type at a time11. The frequency range of absorption by molecules is correlated 
with their structure12. It can be applied to study among others the nucleic acid strands (1000–1250 cm−1), pro-
teins (1500–1560 cm−1, 1600–1700 cm−1), lipids (2800–3000 cm−1) as well as inorganic structures as phosphates 
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(460–1120 cm−1)13. FTIR has many advantages for analyzing of biological structures like the small sample size 
(a few micrograms) required for analysis, no need for pre-processing of tissue (e.g., demineralization, staining), 
no need for tissue dewaxing14,15 and does not require the use of biological markers16. Due to these advantages, 
FTIR can be applied to the very early stages of the disease, before the presence of changes is detectable by light 
microscopy17, and may be suitable for the monitoring a disease course and therapeutic outcome13. They may be 
useful in oncologic diagnostics13,18–20 but also for the comparison of spectra obtained before and after cancer 
chemotherapy11,17,21–23. Data analysis methods allow spectrum transformation, baseline correction, normalization 
and smoothing enable the quantitative analysis of FTIR spectra and have been applied to biology and medicine13.
This retrospective study is based on primary ES bone tissue sections from 27 pediatric patients and demon-
strates that FTIR spectroscopy may be a potential prognostic factor of relapse/progression-free survival and over-
all survival before chemotherapy administration.
Material and Methods
Patients. Twenty-seven patients (age 5–20 years old) with newly diagnosed Ewing sarcoma of bone were 
included in this study. Each patient was treated according to the Euro-EWING protocols in the years 2010–2016 
and their clinical characteristics are presented in Table 1. In each case, identical induction neoadjuvant chemo-
therapy (neo-CTx) of six VIDE cycles (vincristine, ifosfamide, doxorubicin, etoposide) were administrated. 
Surgery was performed in every patient at the Department of Surgical Oncology, Institute of Mother and Child in 
Warsaw, Poland. Microscopically complete resection was possible in the 25 cases. Each histopathological sample 
was verified centrally at the same institution as well as their assessment of response to chemotherapy measured by 
the percentage of viable tumour cells remaining after neo-CTx completion. Good response was defined as greater 
than or equal to 90% necrosis, and a poor response was defined as less than 90% of necrosis. Postoperative treat-
ment was dependent on the individual clinical status of the patient and was also conducted according to Euro-
EWING protocols. There were no deaths observed for reasons other than cancer progression. Informed consent 
was obtained from all patients or their guardians before treatment. This retrospective study was conducted under 
Institutional Review Board (Protocol No. KBET/6/06/2014) from June 2014 at University of Rzeszow. The experi-
mental protocols used in this study were approved by the institutional ethics committees (IECs) of the University 
of Rzeszow, and were carried out in accordance with the approved guidelines.
Samples preparation. Each patient’s samples included 3 types of formalin-fixed paraffin-embedded (FFPE) 
tissues which were analyzed by FTIR spectroscopy. The first FFPE blocks consisted of ES tissues collected during 
a diagnostic biopsy performed before ES therapy. The second group of FFPE blocks consisted of tumour tissue 
after 6 courses of neo-CTX. The third group of FFPE blocks consisted of normal bone tissue from the patients, 
obtained outside the area of the ES infiltration (verified microscopically). All samples were prepared and verified 
by pathologists experienced in ES.
Histological blocks of bone tissue, embedded in paraffin, were sectioned to a thickness of 10 µm using a rotary 
microtome. FFPE tissue sections were then applied to calcium fluoride slides. In the first phase of labelling, sec-
tions were placed on the surface of a tub filled with hot water to allow them to smooth. At this point, the sample 
was gently pulled onto a slide.
Samples were then dewaxed by washing twice in xylene. Samples were rehydrated by rinsing in an alcohol 
series from absolute alcohol (99.8%) through 96%, 80%, and 70% alcohol. Finally, samples were rinsed with dis-
tilled water and dried. Each incubation step lasted for 5 minutes.
FTIR spectroscopy. FTIR spectra were recorded using a Bruker Vertex 70 v Fourier transform infrared spec-
trometer (FT-IR). Tissue specimens were applied to the attenuated total reflection (ATR) plate. Mid-infrared (IR) 
gender
male/female 12/15 pts.
age [yrs]
range
median
<10 yrs old
>=10 yrs old
5–20 yrs
14 yrs
9 pts
18 pts
localized
metastases
- lungs
- bones
- others
11
16
14
5
1
tumor microscopically
incompletely resected 1
histological response
to first line CTx (good/poor) 20/7
local radiotherapy
auto HSCT
17
9
relapses(progressions)/deaths 14/9
follow up time [months]
range
median
14–74
29
Table 1. The clinical characteristic of patients (n = 27).
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radiation was passed through the sample using a single-reflection snap ATR crystal diamond. To achieve 2 cm−1 
of spectral resolution 32 scans were conducted. Spectra were recorded in the range of 800–3500 cm−1. As the 
samples were dewaxed, the air was measured as the background. All measurements were recorded in triplicate. 
Initial data analysis was performed using the program OPUS 7.0 from Bruker Optik GmbH 2011. Spectra were 
normalized, and baseline corrections were made.
Our previous preliminary study24, had revealed that wave-numbers in the range 950–1100 cm−1 are the most 
relevant for monitoring ES clinical course. The wave-number corresponding to the position of absorbance peak 
maximum in this range was subsequently analyzed and compared with clinical data. Three measurements were 
obtained: from ES tumour sample (Tb) and from the normal bone tissue (Tn) outside the tumour area from the 
same biopsy sample. The third one was taken from the tumour resected after the sixth VIDE chemotherapy cycle 
(Tt).
Statistical analysis. The spectral data were analyzed by a two-way ANOVA followed by Tukey’s test to 
determine the correlation between the functional groups of chemical compounds. Correlation between wave-
number and histologic evaluation of percent necrosis were analyzed using the two-tailed Pearson correlation 
coefficient. Overall survival was defined as the time interval from the date of diagnosis to the date of death from 
any cause or to last follow-up date. Progression-free survival (PFS) was taken to be the time from diagnosis until 
disease progression, relapse or last patient contact. The overall survival and progression-free survival curves 
were estimated according to the Kaplan–Meier method and compared using the log-rank test. The parameters 
evaluated in univariate analysis were used as explanatory variables in Cox regression models of progression-free 
survival in the final multivariate models. In the multivariate analyses, only factors identified as significant by the 
univariate analysis were investigated.
The clinical groups were compared by using the Mann–Whitney U test. The optimal wave number cut-off 
point to distinguish a patient with the highest probability of unfavourable outcome (disease progression/relapse/
death) was determined using Receiver Operating Characteristic [ROC] analysis implementing the Youden index. 
It was assumed that the cost of obtaining a false negative is twice as high as the cost of obtaining a false positive. A 
2-sided P value of <0.05 was defined as statistically significant. The calculations were performed using Statistica 
12; StatSoft. 2016. Medical kit version 3.0.
Results
Mean ATR-FTIR spectra of ES primary tumours sampled at diagnosis (Tb) of patients with complete remission 
and with relapse/progression during 3 years from diagnosis are presented in Fig. 1. The median wavenumber of 
maximum absorbance peak from 950–1100 cm−1 FTIR spectrum from ES tumour biopsy before neo-CTx (Tb) 
was 1030 cm−1 for the whole analyzed group and it is significantly lower than the median for normal bone tissue 
(Tn) – 1036.5 cm−1 (p = 0.04). The median wavenumber for resected ES tumour after neo-CTx completion (Tt) 
was 1031 cm−1 but this is not statistically significant to both Tb and Tn.
The obtained results (the medians with range) for Tb, Tn and Tt wave-number values, as well as the shifts of 
the peaks expressed as differences Tb − Tn and Tt − Tb, are presented in Table 2. No important differences were 
Figure 1. (A) Mean spectra of ES primary tumors sampled at diagnosis (Tb) of patients with complete 
remission (a) and with relapse/progression during 3 years from diagnosis (b) with assignment of bands to the 
main chemicals groups composing macromolecules. The symbols νs, νas, δs stand for symmetric stretching 
vibrations, asymmetric stretching vibrations, and symmetric bending vibrations, respectively. The difference 
spectrum (c) is obtained by subtracting spectra of patients with relapse/progression from spectra of patients in 
complete remission. Measuring range 800–1800 and 2800–3500 cm−1. (B) Mean spectra FTIR of the maximum 
absorbance peak from 950–1100 cm−1 range in ES tumors at diagnosis for: patients with complete remission (a) 
and with relapse/progression during 3 years (b) from diagnosis. Measuring range 900–1200 cm−1.
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observed among patient subgroups distinguished according to clinical features with exception of significant dif-
ferent values of Tb − Tn and Tt − Tb in patients younger and older than 15 years old and Tt − Tb between boys 
and girls. The treatment modalities, like autologous stem cell transplantation or radiotherapy as well as VAC 
(vincristine, dactinomycin, cyclophosphamide) versus VAI (vincristine, dactinomycin, ifosfamide) adjuvant 
chemotherapy cycles had no significant impact on the outcome. There were observed no correlations between 
necrosis after neo-CTx completion percentage and respectively: Tb (R Spearman = −0.211; p = 0.29), Tt (R 
Spearman = 0.08; p = 0.67), Tn (R Spearman = −0.213; p = 0.37), Tb − Tn (R Spearman = −0.11; p = 0.64) and 
Tt − Tb (R Spearman = 0.27; p = 0.17).
Unexpectedly, very significant differences in Tb values were observed between patients with relapse/disease 
progression and those being in complete remission. A similar significant difference was visible in the median 
Tb values between children who died and survivors. Parameters like Tb − Tn and Tt − Tb were also significantly 
different in patients with relapsed/progression compared to the survivors.
Receiver operating characteristic curves were used to establish the most suitable values for Tb, Tb − Tn and 
Tt − Tb cut-off which could separate the group of patients with poor prognosis (with ES progression/relapse or 
death). According to this Analysis we established the following cut-off values: Tb ≥ 1027 cm−1, Tt − Tb < + 1 cm−1 
(what is equal with the shift of the maximum peak wavenumber after neo-CTx to the left or up to 1 cm−1 to the 
right) and Tb − Tn ≥ −1 cm−1 (the shift of the normal bone tissue peak to the right or up to 1 cm −1 to the left of 
the Tb position). The area under curve (AUC) were respectively: 0.865; 0.832 and 0.901.
The median follow-up for the analyzed patients was 29 months (14–74 months). The 3-year progression-free 
survival rate was 41,36%, and the 3-year overall survival (OS) rate was 56,66%. Considering only well-known, 
classical risk factors in ES25 (presented in Table 2), only patient gender had a significant impact on 3 yrs sur-
vival: Overall survival (p = 0.01) in the univariate analysis and nearly significant on progression-free survival 
at 3 yrs (p = 0,06). Across the whole patient group, the median Tb value and differences Tb − Tn and Tt − Tb 
were found to be strongly related to outcome (Table 3), e.g. 100% of patients with Tb ≥ 1027 cm−1 (n = 15) had 
progressed or relapsed during the 3 yrs follow up period compared to 82% progression-free survival in patients 
with Tb < 1027 cm−1 in this period (n = 12; log-rank p = 0.00058). Kaplan-Meier plots for progression-free sur-
vival and overall survival according to variables established in ROC analysis: Tb, Tb − Tn and Tt − Tb values are 
presented in Fig. 2.
In the multivariate analysis for percentage progression-free survival (Table 4), Tb values of 1027 cm−1 or more 
remains the most significant independent prognostic factor (p = 0.004; HR = 10.41; 95% CI 2.07–52.2), and Tt 
Variable (n=)
Tb [cm−1] 
median (range) p
Tt [cm−1] 
median (range) p
Tn* [cm−1]
median (range) p
Tt − Tb [cm−1]
median (range) p
Tb − Tn* [cm−1]
median (range) p
gender
male (12) 1026.0 (1019–1031)
0.37
1031.0 
(1018–1080)
0.68
1040 (1029–1080)
0.27
−2,0
(−24–+29)
0.05
−0,5
(−26–+27)
0.24
female (15) 1030.5 (989–1081)
1031.0 
(1023–1082) 1036 (1014–1080) +5.0 (−3–+33)
−8.0 
(−19–+18)
age
<15 yrs old (17) 1026.0 (989–1079)
0.14
1031.0 
(1018–1072)
0.94
1041.0 (1027–1080)
0.94
+6 (−7–+33)
0.008
−9.0 (−19–1)
0.024
≥15 yrs old (10) 1031.5 (1024–1081)
1031.0 
(1020–1077) 1031.0 (1014–1079) −2.5 (−24–+7)
+2.0 
(−26–+27)
disease
local (11) 1030.0 (989–1061)
0.79
1031.0 
(1018–1082)
0.15
1031.0 (1014–1080)
0.76
+4.0 (−7–+29)
0.61
−3.0 
(−26–+18)
0.82
metastatic (16) 1028.0 (1019–1081)
1032.0 
(1023–1080) 1044.0 (1027–1080) +5.5 (−24–+33)
−7.0 
(−19–+27)
site of tumor
peripheral (20) 1028.5 (989–1079)
0.57
1031.0 
(1018–1080)
0.06
1036.5 (1014–1080)
0.60
+3.0 (−24–+29)
0.20
−6.5 
(−26–+27)
0.78
axial/pelvis (7) 1030.0 (1020–1081)
1050.0 
(1030–1082) 1039.5 (1029–1080) +5.0 (−4–+33) −6.0 (−19–+2)
necrosis
favorable 
(≥90%) (20)
1026.5 (1019–
1079)
0.93
1031.0 
(1023–1082)
0.13
1036.5 (1014–1080)
0.44
+5.5 (−24–+33)
0.08
−7.0 
(−19–+27)
0.62
unfavorable 
(<90%) (7)
1030.0 
(989–1081)
1024.0 
(1018–1077) 1040.5 (1031–1079) −4.0 (−7–+29) −0.5 (−26–+2)
relapse/progression
yes (14) 1031.5 (1025–1081)
0,0007
1031.5 
(1023–1080)
0.37
1031.5 (1014–1080)
0.73
−0.5 (−24–+14)
0.0022
−1.0 
(−14–+27)
0.0015
no (13) 1024.0 (989–1061)
1031.0 
(1018–1082) 1044.5 (1029–1080) +7.0 (−4–+33) −16.0 (−26–3)
death
yes (9) 1033.0 (1030–1081)
0.0012
1034.0 
(1024–1080)
0.035
1039.0 (1029–1080)
0.43
0.0 (−24–+20)
0.076
−0.5 
(−18–+27)
0.058
no (18) 1025.0 (989–1061)
1031.0 
(1018–1082) 1036.5 (1014–1080) +5.5 (−6–+33)
−8.0 
(−26–+18)
total (27) 1030.0 (989–1081) —
1031.0 
(1018–1082) — 1036.5 (1014–1080) — +4.0 (−24–+33) —
−6.5 
(−26–+27) —
Table 2. The wavenumber median of maximum absorbance peak from 900–1100 cm−1 FTIR spectrum from 
ES tumor before (Tb), after (Tt) neo-CTx completion and normal bone tissue (Tn) at diagnostic biopsy. The 
wavenumbers were compared using U Mann-Whitney test. Significant differences are indicated in bold. *The 
measurement of FTIR spectrum for normal bone tissue was possible to obtain in 20 cases.
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− Tb < +1 cm−1 emerged as the second most important independent variable (p = 0.034; HR = 6.57; 95% CI 
1.15–37.54). The p-value of male gender was not significant in this analysis.
Discussion
ATR-FTIR spectroscopy can reveal structural and compositional changes of cells at the molecular level. These 
changes, arising from carcinogenesis or the action of cytotoxic drugs, cause alteration of the levels of biomole-
cules within the cells. Due to the different vibrational modes of these biomolecules, a change in the bulk vibra-
tional spectra of the tissue occurs. Chemometric statistical methods can allow this spectral change data to be used 
for exploratory and modelling purposes allowing normal or malignant cells to be differentiated based on their 
spectral characteristics18.
The analysis of bone samples can be costly and time-consuming. In contrast, some significant advantages of 
this method are its speed and low-cost. We have shown previously15 that paraffin dewaxing can be avoided in the 
sample preparation procedure which decreases the risk of bone material damage facilitating the use of the method 
in routine and scientific analyses.
To date, there have been no published attempts to apply any vibrational spectroscopic method (such as infra-
red, near-infrared and Raman) to the study of Ewing Sarcoma for progression modelling. Wald et al.11, have 
demonstrated that unsupervised analysis of the FTIR spectra evidence permitted the assignment of patients with 
primary melanoma into two groups that correlated to the clinical responsiveness of the patients to dacarbazine 
used as a first-line treatment. A supervised model resulted in correct identification of patient status (responder/
non-responder) in 83% of cases. Furthermore, the spectra revealed a key modification in the nature and quantity 
of lipids in the cells of both groups. Zawlik et al. have reported the application of a focal-plane-array Fourier 
transform infrared (FPA-FTIR) spectroscopy combined with principal component analysis (PCA) that allowed 
the effect of chemotherapy on triple-negative breast cancer patients to be monitored21. The PCA results obtained 
using the FPA-FTIR spectral data collected before and after the chemotherapy revealed discriminatory features 
that were consistent with the pathologic and clinical responses to chemotherapy, indicating the potential of the 
technique as a monitoring tool for observing chemotherapy efficacy. Tolstorozhev et al. have found that infrared 
spectroscopic analysis can be used in the diagnosis and treatment monitoring of cancers of various organs at 
the molecular level22. They found that when lung malignancy was treated with palladium complexes of meth-
ylenediphosphonic acid, the spectroscopic signs of the presence of metastases in the lungs disappear, and the 
infrared spectrum of the lung tissue after treatment practically coincides with the spectrum of healthy lung tissue. 
Significant changes in cellular lipid composition were observed by Denbigh et al. upon treatment of K562 and 
HL60 cells (acute myeloid leukaemia) with the drug combination of bezafibrate and medroxyprogesterone ace-
tate when examined by ATR-FTIR, Synchrotron radiation FTIR (S-FTIR) and Raman micro-spectroscopy23. The 
emerging diagnostic applications of FTIR spectroscopy are growing as the field matures and it has been applied 
successfully to the study of breast cancer17, lung cancer26, ovarian cancer27, brain tumors28, cervical cancer29, 
Variable n PFS 3yrs p OS 3yrs p
site of tumor
peripheral
axial/pelvis
20
7
0.33
0.69
0.20 0.58
0.53
0.59
age
< 15
>= 15 yrs old
17
10
0.50
0.27
0.19 0.59
0.47
0.47
gender
male
female
12
15
0.31
0.52
0.05 0.32
0.73
0.01
disease
local
metastatic
11
16
0.40
0.45
0.92 0.58
0.54
0.65
necrosis
favorable (≥90%)
unfavorable (<90%)
20
7
0.50
0.21
0.31 0.67
0.23
0.1
radiotherapy RTx
yes
no
17
10
0.35
0.55
0.25 0.59
0.87
0.07
autoHSCT
yes
no
8
19
0.16
0.55
0.23 0.44
0.80
0.05
adjuvant CTx
VAI
VAC
18
6
0.43
0.41
0.57 0.71
0.45
0.16
Tb≥1027 [cm−1]
Tb< 1027 [cm−1]
15
12
0.00
0.82 0.00058
0.21
1.00 0.00059
Tt-Tb ≥ +1 [cm−1]
Tt-Tb < +1 [cm−1]
18
9
0.65
0.00 0.00277
0.69
0.21 0.026
Tb-Tn ≥ −1 [cm−1]*
Tb-Tn < −1 [cm−1]*
8
12
0.00
0.55 0.01
0.30
0.73 0.015
Table 3. Prognostic values of classical and spectral parameters on univariate analysis. Significant differences are 
indicated in bold. *The measurement of FTIR spectrum for normal bone tissue was possible to obtain in 20 cases.
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gastric cancer30, colon cancer31, prostate cancer32. The preliminary results of FTIR spectroscopy application in 
diagnostics of a bone tumour have been reported in our previous studies15,24 emphasizing the applicability of 
FTIR to all tissue types.
The “bio-fingerprint region” (1800 cm−1 to 900 cm−1) of the mid-IR spectrum contains the fundamental 
vibrational modes of key chemical bonds that may be exploited to provide a rapid non-destructive, screening 
approach to diagnosis33. We, therefore, sought to identify specific spectral features in ES tissue as the equivalent of 
a traditional cancer biomarker. We showed the strong predictive value of the wavenumber of the maximum peak 
absorbance in the range of 1100–900 cm−1 in ES samples at diagnosis before neo-CTX administration (Tb), as 
well as the wave numbers difference between this peak position and its equivalents in the resected tumor sample 
after neo-CTx completion (Tt − Tb) or from the normal bone tissue sample (Tb − Tn) taken from the same patient. 
Unexpectedly, in our small cohort of patients these features are the strongest independent factors for outcome 
prognosis (PFS) in the analyzed group. The progression-free survival and overall-survival times of these patients 
could be predicted more accurately using these FTIR spectral parameters than from the standard, clinical prog-
nostic factors like presence of distal metastases at diagnosis, the primary tumor localization (axial vs peripheral) 
and the histological response (greater than or equal to 90% necrosis after neo-CTx). From the clinical features, 
only gender was significantly predictive for prognosis in the univariate and multivariate analyses. We believe 
that the small size of our analyzed patient group limits the prognostic superiority of this spectral parameter over 
routinely used risk factors.
In our previous, preliminary study24 we postulated that the shift of the maximum absorbance peak in the 
range 1100 cm−1–900 cm−1, which was related to chemotherapy response, is dependent on signals derived from 
the phosphate group in the sample. Presently, based on the greater results of the spectral analysis presented 
herein, we have to revise this conclusion and state that it is impossible to unequivocally attribute this peak only 
to one chemical structure as the vibrations of different molecular components of a cell overlap and the spectrum 
Figure 2. Kaplan–Meier curves comparing progression-free survival (PFS) (a–d) and overall survival (OS) (e–h)  
in patients according to the wave-number corresponding to the position of absorbance peak maximum 
in the range 950–1100 cm−1:  from Ewing Sarcoma tumour sample (Tb) and the shifts of the peaks expressed as 
differences Tb − Tn (Tn – the wave-number from the normal bone tissue); Tt − Tb (Tt  - the wave-number from 
tumour resected after 6th VIDE chemotherapy cycle). (b) and f) Tb ≥ 1027 cm−1 (Blue) vs < 1027 cm−1 (Red); 
(c) and g) Tt − Tb ≥ +1 cm−1 (Red) vs Tt − Tb < +1 cm−1 (Blue) (d) and (h) Tb − Tn < −1 cm−1 (Red) vs Tb − 
Tn > = −1 cm−1 (Blue).
Parameter
Risk of relapse/progression p=0,00005
Wald test (p) HR 95% C.I. HR
male gender 0.69 1,37 0.29 6.55
Tb ≥ 1027 [cm−1] 0.004 10.41 2.07 52.20
Tt-Tb < +1 [cm−1] 0.034 6.57 1.15 37.54
Tb-Tn ≥−1 [cm−1]* 0.74 1.33 0.24 7.53
Table 4. Multivariate Cox Regression Analysis for PFS with Backward Wald Statistics Method (27 Patients). 
Significant results are indicated in bold. *Tb-Tn measurements in 20 cases (p = 0,014).
www.nature.com/scientificreports/
7SCIENTIFIC REPORtS |  (2018) 8:12299  | DOI:10.1038/s41598-018-29795-8
thus reflects the average biochemical composition13. Conclusive biological explanation of the tissue-section 
spectral results is impossible without inviting over-analysis. Due to this limitation, the addition of the other 
analytical instruments like electron paramagnetic resonance spectroscopy, nuclear magnetic resonance spec-
troscopy, Raman spectroscopy or X-ray absorption near edge structure is necessary for a better understanding 
of phenomena connected with ES aetiology and clinical course, occurring in the tumour cells. Presently, we can 
only speculate that the maximum absorbance peak responsible for outcome prediction in ES can be associated 
to the biochemical components containing phosphates like nucleotides from DNA or RNA, phospholipids from 
cell membranes, phosphorylated proteins, phosphate esters but may also arise from hydroxyapatite which is the 
fundamental bone component13,34,35. Likewise, ES cells contain glycogen particles with corresponding FTIR spec-
troscopy wave-numbers from 1000–1100 cm−1 13,26 and it is thus likely that glycogen contributes to the final shape 
and position of this peak.
Conclusions
The identification of clinically applicable methods that allow the adoption of risk-adapted therapeutic approaches 
is an unmet need in the treatment of bone cancers such as Ewing Sarcoma. In this retrospective study, we demon-
strate that selected spectral FTIR parameters related with wave-numbers corresponding to maximum peak 
absorbance from 950–1100 cm−1 range may have a strong predictive value on the outcome (progression free sur-
vival, overall survival) of patients with Ewing sarcoma of bones treated according to VIDE and VAI/VAC based 
chemotherapy regimens.
Significantly two of the three described spectral parameters (Tb and Tb − Tn) can be obtained prior to the the 
start of the treatment. It may, therefore, be possible to assess the likelihood of treatment success, thus allowing 
alternate treatment regiments to be undertaken in patients whose predicted response to VIDE and VAI/VAC 
based chemotherapy is poor. Moreover, as ES is rare and it presents with symptoms similar to other conditions 
patients are frequently misdiagnosed or patient diagnosis is delayed. In addition, although the conventional 
immunohistochemical marker for Ewing Sarcoma (CD99) has high sensitivity it is also low specificity for the 
disease. We therefore feel that FTIR may offer an additional, complementary tool for the improvement of ES 
diagnostics.
Although it is not possible from this study to determine the potential levels of specificity and sensitivity when 
using FTIR to discriminate prognostic outcome our results suggest that it is worthy of further research. We there-
fore hope to investigate this further on more numerous and diverse patient groups in the hope that these spectral 
features may be strongly predictive for the identification of individuals with the worst prognosis.
Compliance with ethical standards. All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutional and/or national research committee and with 
the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was 
obtained from all individual participants included in the study.
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